Joost C.M. Uitdehaag, Jos de Man, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil, Winfried R. Mulder, Michelle Muller, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu,
Joeri J.P. de Wit, Erik Ensing, Rogier C.
Joost C.M. Uitdehaag, Winfried R. Mulder, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil, Daphne Montizaan, Michelle Muller, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik
The Crossfire team will present 3 posters at the American Association for Cancer Research (AACR) annual meeting 2024. We will highlight the latest data on our best-in-class macrocyclic BTK inhibitor CFON-026, our novel Degrader Antibody Conjugate (DAC) technology, and our
Today Crossfire Oncology B.V. (Crossfire) has entered its brand-new state-of-the-art chemistry and molecular biology laboratories at the Marie Curie Building (Pivot Park, Oss). The new facilities will enable Crossfire to expand their activities in developing kinase Degrader Antibody Conjugates (DACs)